What does the June pattern show at a glance?
At a glance, the June pattern points to tighter sourcing signals in narrow hardware families than in broad 510(k)-cleared record volume alone. Under Agence Octo methodology, repeated 510(k) activity in Respiratory & Sleep and selected rehab or sensor-adjacent categories is a stronger scouting indicator than diagnostics-heavy volume by itself. ([Agence Octo methodology])
Five of the top 10 companies are US-based. Two are China-based. One each comes from Singapore, New Zealand, and Sweden. [Bucket 1: FDA CDRH public database]
Category concentration is even tighter. Seven of the 10 companies sit in Respiratory & Sleep. Three appear in Rehab & Neurotech. Three appear in Home Diagnostics. One appears in Wearable Biosensors. These category counts can overlap because the same filing entity may be mapped to more than one Agence Octo lens. [Bucket 1: FDA CDRH public database; Bucket 4: Agence Octo category lens mapping]
| Lede claim | Supporting June 2026 snapshot evidence | Source label |
|---|---|---|
| Narrow hardware-family clusters are more useful than raw volume alone | Top 10 holders account for 65 cleared 510(k) submissions, but Agence Octo's buyer read prioritizes repeat filings within one device family over leaderboard rank alone | [Bucket 1: FDA CDRH public database; Bucket 4: Agence Octo methodology] |
| Respiratory & Sleep is the clearest June cluster | Seven of the top 10 companies fall into Respiratory & Sleep under Agence Octo category lens mapping | [Bucket 1: FDA CDRH public database; Bucket 4: Agence Octo category lens mapping] |
| Diagnostics-heavy portfolios need more caution for OEM outreach reads | Home Diagnostics appears among top-10 entities, but Agence Octo treats diagnostics-heavy portfolios as a weaker direct OEM-scouting fit than narrow hardware clusters | [Bucket 1: FDA CDRH public database; Bucket 4: Agence Octo methodology] |
| China-based repeat filers are present but selective | Two China-based companies appear in the top 10, both in concentrated hardware categories rather than diffuse portfolios | [Bucket 1: FDA CDRH public database; Bucket 4: Agence Octo methodology] |
| Representative entity or cluster | Country | Agence Octo category lens | Representative cluster output | Buyer read |
|---|---|---|---|---|
| Fisher & Paykel Healthcare, Ltd. | New Zealand | Respiratory & Sleep | Repeated mask or cannula-related clearances | Suggests maintained depth in a narrow respiratory family, not just one filing. ([Agence Octo methodology]) |
| Sleepnet Corporation | United States | Respiratory & Sleep | Repeated mask-related clearances | Useful for screening product-family continuity. ([Agence Octo methodology]) |
| Unimed Medical Supplies, Inc. | China | Wearable Biosensors | Repeated SpO2 sensor clearances | Notable for screening possible sensor manufacturing depth; does not prove white-label readiness or OEM availability. ([Agence Octo methodology]) |
| Kunshan Hi-Fortune Health Products Co., Ltd. | China | Rehab & Neurotech | Repeated wheelchair-related clearances | Stronger sourcing signal than a one-off filing in a heavier-maintenance category. ([Agence Octo methodology]) |
| Cepheid / Roche Molecular Systems / Abbott Molecular | United States / Sweden / United States | Home Diagnostics | Molecular diagnostics-heavy portfolios | Real market activity, but often a weaker direct OEM-outreach fit for smaller hardware-led brands under Agence Octo methodology. ([Agence Octo methodology]) |
That matters because clusters can be more informative than isolated filings.
A single clearance can mean one launch. A repeated cluster in one device family can indicate a maintained product line, documentation discipline, and active US-market orientation. ([Agence Octo methodology])
How does the Agence Octo Clearance-Cluster Screen work?
Use three checks together.
| Check | What Agence Octo looks for | What it suggests |
|---|---|---|
| Repeat filings in one family | Multiple cleared 510(k)s around the same product architecture or accessory line | The company may be maintaining a platform, not testing a single SKU. ([Agence Octo methodology]) |
| Country + company posture | Filing entity location paired with product pattern | Foreign filers in repeat device categories can be worth screening as possible export-capable manufacturers; US filers can be worth reading first as brand or system owners. This is a sourcing signal, not a legal classification. ([Agence Octo methodology]) |
| Category concentration | Clearances concentrated in one lens such as sleep, respiratory, rehab, or home diagnostics | Narrow concentration usually gives a cleaner sourcing thesis than one-off filings across unrelated areas. ([Agence Octo methodology]) |
No single check proves OEM capability.
Watch the stack, not any single signal.
What do the June leaders suggest?
Fisher & Paykel Healthcare, Ltd. and Sleepnet Corporation both sit inside Respiratory & Sleep with repeated mask or cannula-related clearances. That kind of repetition suggests line depth inside a tight product family rather than a one-time filing event. [Bucket 1: FDA CDRH public database; Bucket 4: Agence Octo category lens mapping]
Unimed Medical Supplies, Inc. stands out for a China-based filing profile plus repeated SpO2 sensor clearances. That combination is notable for buyers screening possible wearable biosensor manufacturing depth under Agence Octo methodology. It does not prove white-label readiness. It sets the burden of proof. The tighter the product family match to your target device, the more useful the company becomes for further OEM screening. ([Agence Octo methodology])
Kunshan Hi-Fortune Health Products Co., Ltd. shows repeated wheelchair-related clearances from China. Repetition in a capital-equipment-adjacent rehab category can be a stronger sourcing signal than a single filing because the documentation and product maintenance burden is heavier. ([Agence Octo methodology])
Cepheid, Roche Molecular Systems, and Abbott Molecular are different. Their presence in the FDA 510(k) data is real and important, but diagnostics-heavy portfolios more often indicate platform ownership, assay ecosystems, and established commercialization structures that may not map neatly to OEM outreach for a smaller hardware-led brand. That is an Agence Octo sourcing interpretation, not a statement about regulatory status or commercial openness. [Bucket 1: FDA CDRH public database; Bucket 4: Agence Octo methodology]
Clearance count is a leaderboard metric. Cluster shape is the scouting metric.
What should buyers notice first?
Buyers should notice first which companies show repeated filings inside a narrow hardware family, because that pattern can be a cleaner OEM-scouting signal than broad filing volume alone. Under Agence Octo methodology, this month that points more clearly toward selected respiratory, sensor, and rehab names than toward broad diagnostics portfolios. ([Agence Octo methodology])
If you are scouting counterparties, start with companies whose filings repeat inside a narrow hardware family.
This month, that points more clearly toward names like Unimed Medical Supplies, Kunshan Hi-Fortune Health Products, Sleepnet, and parts of Fisher & Paykel's respiratory line than toward broad diagnostics portfolios. That does not mean the first group is available for private-label work. It means the sourcing hypothesis is cleaner. ([Agence Octo methodology])
If you are a brand operator, the useful question is not "Who has FDA 510(k) Class II clearance?"
The useful question is "Who shows repeatable evidence of maintaining a product family that resembles what I want to source?"
Practical next-step checklist for outreach
- Match the cleared product family to your target device architecture before outreach.
- Check whether the company shows repeat filings in one narrow family rather than scattered categories.
- Treat diagnostics-heavy portfolios as lower-confidence OEM-outreach candidates unless your need is assay or platform aligned.
- Use FDA cluster evidence as a first-pass screen, then verify commercial model, manufacturing role, and partnership fit directly. ([Agence Octo methodology])
- For a fuller counterparty screen, pair this FDA view with Agence Octo Periscope trade, registry, and company-profile checks before outreach. ([Agence Octo methodology])
What are the June 2026 sourcing takeaways?
Three signals stand out in this snapshot:
- Respiratory & Sleep is the densest cluster. Seven of the top 10 companies sit there. [Bucket 1: FDA CDRH public database; Bucket 4: Agence Octo category lens mapping]
- China-based repeat filers are present, but selective. Only two China-based companies make the top 10, and both are concentrated in clear hardware categories rather than diffuse portfolios. [Bucket 1: FDA CDRH public database]
- Diagnostics-heavy volume needs caution in sourcing reads. High filing counts in molecular diagnostics show market activity, but they do not automatically translate into approachable OEM opportunity under Agence Octo methodology. ([Agence Octo methodology])
That is why Agence Octo treats FDA 510(k) data as one layer, not the answer.
A filing tells you someone cleared. The cluster tells you where to look next.